<DOC>
	<DOCNO>NCT01900717</DOCNO>
	<brief_summary>To evaluate tolerance efficacy bevacizumab treatment MCRC elderly patient , propose phase II randomise study compare chemotherapy + bevacizumab arm chemotherapy alone arm first-line treatment MCRC patient age 75 year old . This study destine continue phase III trial arm meet selection criterion show benefit treatment bevacizumab combine chemotherapy .</brief_summary>
	<brief_title>Evaluation Bevacizumab Combination With First-Line Chemotherapy Patients Aged 75 Years Older With Metastatic Colorectal Adenocarcinoma ( Prodige20 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patients age 75 year old ECOG ≤2 histologically proven unresectable metastatic colorectal adenocarcinoma Measurable lesion accord RECIST criterion Absence prior chemotherapy metastatic disease . Adjuvant chemotherapy follow resection primary tumor authorize complete 6 month previously Patients treated anticoagulant ( coumadin , warfarin ) include close surveillance INR ensure . A change lowmolecularweight heparin preferable long indication respect Completed geriatric self‐questionnaire Completed `` Team '' geriatric questionnaire ( include Spitzer QoL Index ) Written informed consent Estimated life expectancy &lt; 3 month Nonresolved intestinal occlusion sub‐occlusion Cerebral metastasis Other evolutive malignant tumor ( nonstabilized cancer le 2 year ) Evolutive gastroduodenal ulcer , wound bone fracture Active heart disease : uncontrolled hypertension , myocardial infarction In previous 6 month , angina , noncompensated congestive heart failure Major surgery , except biopsy , irradiation 4 week precede start treatment Polynuclear neutrophils &lt; 1500/mm3 , platelet &lt; 100 000/mm3 24h proteinuria &gt; 1g History arterial thromboembolic event ( cerebrovascular accident , transient ischemic attack , subarachnoid hemorrhage ) 12 month precede first dose bevacizumab History distal visceral ischemia ≥ grade 2 12 month precede first dose bevacizumab History lifethreatening pulmonary embolism 6 month precede first dose bevacizumab Impossibility ensure regular followup</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>